Activity-Based Nanosensors for Noninvasive Transplant Rejection Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting acute and chronic transplant rejection are invasive, lack sensitivity, and fail to directly measure anti-graft immune activity early on, necessitating a noninvasive approach to monitor T cell cytotoxicity and related immune conditions.
Innovation Solution
Development of activity-based nanosensors comprising scaffolds linked to detectable protease-specific peptides that accumulate in bodily fluids upon protease activity, allowing for noninvasive detection of transplant rejection by cleavage and subsequent accumulation of detectable peptides in urine, lymphatic fluid, blood, or saliva.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If core tissue biopsy is used to diagnose acute cellular rejection, then diagnostic accuracy is improved, but patient morbidity and procedural invasiveness increase
Solution Approach 1:
The patent uses protease-specific detectable peptides as intermediary molecules that indirectly detect T cell cytotoxicity. These peptides are cleaved by proteases released during T cell-mediated graft damage, and the cleaved peptides accumulate in bodily fluids where they can be noninvasively detected, serving as a mediator between the immune response and diagnostic measurement
Solution Approach 2:
The patent replaces the mechanical tissue biopsy procedure with a biochemical detection system. Instead of physically extracting and examining tissue samples, the method uses protease-specific peptides that undergo chemical cleavage in response to protease activity, with the cleavage products detectable in bodily fluids through noninvasive sampling
2Object-affected harmful factors
If noninvasive biomarker methods are used to monitor graft health, then patient morbidity is reduced, but detection sensitivity and ability to measure early immune activity decrease
Solution Approach 1:
The patent changes the detection parameter from measuring organ function downstream effects (like blood urea nitrogen or serum creatinine) to measuring protease activity directly. By using protease-specific detectable peptides, the system detects the actual immune activity parameter (protease release) rather than secondary consequences, significantly improving detection sensitivity for early rejection
Solution Approach 2:
The cleaved detectable peptides serve as intermediary signal molecules that amplify the detection signal. The accumulation of these cleaved peptides in bodily fluids creates a measurable signal that is more sensitive than traditional biomarkers, allowing early detection of immune activity before significant organ dysfunction occurs
3Ease of operation
If traditional biomarkers like blood urea nitrogen are used, then noninvasive monitoring is achieved, but the ability to detect early anti-graft immune activity is lost
Solution Approach 1:
The patent implements preliminary detection by measuring protease activity at the moment it occurs during early rejection. The protease-specific detectable peptides are designed to be cleaved immediately when proteases are released by activated T cells, allowing detection of immune activity at its onset rather than waiting for downstream functional consequences to manifest
Solution Approach 2:
The detectable peptides act as temporal intermediaries that capture and preserve the timing information of protease release. The cleaved peptides accumulate in bodily fluids, preserving the signal of early immune activity and allowing delayed noninvasive detection of events that occurred earlier, effectively reducing the detection time lag
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early and sensitive detection of acute and chronic transplant rejection, as well as immune conditions like GvHD and autoimmune diseases, by amplifying detection signals in bodily fluids, potentially reducing the need for invasive biopsies and improving patient outcomes.
Implementation Method 1
compositions comprising scaffolds (such as for example and not limitation, protein scaffolds, polymer scaffolds, and particles (e.g., a microparticle or nanoparticle)) linked to protease-specific detectable peptides that can be administered to transplant recipients and used to detect acute and chronic transplant rejection by cleavage of the composition via the accumulation of the detectable peptides locally at the site of cleavage and/or in a bodily fluid
Data Source
AI summary
An activity-based nanosensor composition for detecting protease activity comprising a cleavable detectable substrate and methods of use are disclosed.